Benzinga | Oct 4, 2021 08:08AM EDT

Rain Therapeutics To Present On Milademetan At 2021 AACR-NCI-EORTC Virtual International Conference On Molecular Targets And Cancer Therapeutics

NEWARK, Calif., October 1, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., (NASDAQ:RAIN), ("Rain"), a late-stage company developing precision oncology therapeutics, today announced it will be presenting three posters highlighting its oral mouse double minute 2 (MDM2) inhibitor, milademetan, and the importance of MDM2 as a therapeutic target at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics being held October 7-10, 2021.



Additional presentation details can be found below:

Title: MDM2 gene amplification as a predictive biomarker for the MDM2 inhibitor milademetan

Presenter: Vijaya Tirunagaru, Ph.D., Sr. Vice President and Head of Research, Rain Therapeutics, Newark, CA

Presentation Number: P210

Date: October 7, 2021

Title: Milademetan is a potent, murine double minute 2 (MDM2) inhibitor, highly active in TP53 wild-type (p53WT) Merkel cell carcinoma (MCC) cell lines

Presenter: Varsha Ananthapadmanabhan, Ph.D., Post-Doctoral Fellow, Dana Farber Cancer Institute, Brigham and Women's Hospital and Harvard Medical School., Boston, MA

Presentation Number: P203

Date: October 7, 2021

Title: The MDM2 inhibitor milademetan induces synthetic lethality in GATA3 mutant, ER positive breast cancer

Presenter: Vijaya Tirunagaru, Ph.D., Sr. Vice President and Head of Research, Rain Therapeutics, Newark, CA

Presentation Number: P215

Date: October 7, 2021

Copies of each poster will be available by visiting the "Events & Presentations" section of the Rain website.

Investor Webinar

Rain will host an R&D day webinar on Tuesday, November 9, 2021, at 11:00 am ET featuring members of Rain's management team and several key opinion leaders to discuss Rain's research and development program, as well as select clinical and preclinical data in more detail.

Interested parties can register for the webinar here.